BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25311306)

  • 1. Joint modeling of longitudinal health-related quality of life data and survival.
    Ediebah DE; Galindo-Garre F; Uitdehaag BM; Ringash J; Reijneveld JC; Dirven L; Zikos E; Coens C; van den Bent MJ; Bottomley A; Taphoorn MJ
    Qual Life Res; 2015 Apr; 24(4):795-804. PubMed ID: 25311306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
    J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    ; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
    J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.
    Wang M; Cairncross G; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Mehta M; Curran W; ; ; ; ;
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):662-9. PubMed ID: 19783377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
    BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
    J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Gonzalez-Aguilar A; Reyes-Moreno I; Peiro-Osuna RP; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E
    Rev Neurol; 2018 Oct; 67(8):293-297. PubMed ID: 30289152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
    J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P; Wick W; Weller M
    Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
    Macdonald DR; Gaspar LE; Cairncross JG
    Ann Neurol; 1990 May; 27(5):573-4. PubMed ID: 2360797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
    Buckner JC; Shaw EG; Pugh SL; Chakravarti A; Gilbert MR; Barger GR; Coons S; Ricci P; Bullard D; Brown PD; Stelzer K; Brachman D; Suh JH; Schultz CJ; Bahary JP; Fisher BJ; Kim H; Murtha AD; Bell EH; Won M; Mehta MP; Curran WJ
    N Engl J Med; 2016 Apr; 374(14):1344-55. PubMed ID: 27050206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
    J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
    J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
    Esparragosa Vazquez I; Ndiaye M; Di Stefano AL; Younan N; Larrieu-Ciron D; Seyve A; Picart T; Meyronet D; Boutet C; Vassal F; Carpentier C; Figarella-Branger D; Dehais C; Forest F; Rivoirard R; Ducray F;
    Eur J Neurol; 2023 Sep; 30(9):2879-2883. PubMed ID: 37204066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.